ZBIO Zenas BioPharma
Price Chart
Executive Summary
Zenas BioPharma announced that the Phase 3 INDIGO trial of obexelimab in IgG4-Related Disease met its primary endpoint and all four key secondary endpoints. The trial showed a highly statistically significant 56% reduction in the risk of flare versus placebo. An oral presentation of the full safety and efficacy data is scheduled for June 4 at the EULAR 2026 Congress.
Actionable Insight
The INDIGO data presentation at EULAR on June 4 is a key catalyst — full dataset and expert Q&A may clarify differentiation vs standard of care. Monitor for BLA filing timeline and potential partnership interest. SLE topline in Q4 2026 adds a second catalyst. Given the high win rate on prior bullish calls on this ticker is weak (33%), position sizing should account for binary risk.
Key Facts
- Phase 3 INDIGO trial met primary endpoint with 56% reduction in flare risk (HR 0.443; p=0.0005).
- All four key secondary endpoints were met with high statistical significance.
- Obexelimab was well tolerated; fewer Grade ≥3 TEAEs (11.3% vs 23.7%) and SAEs (10.3% vs 18.6%) versus placebo.
- Topline results from Phase 2 SLE trial expected Q4 2026.
- Data to be presented at EULAR 2026 Congress on June 4, 2026.
Financial Impact
Positive read-through for a registrational Phase 3 trial in a first-line indication; potential peak sales in the hundreds of millions if approved, though no financial figures were disclosed.
Risk Factors
- IgG4-RD is an orphan disease; commercial adoption depends on pricing and payer coverage.
- Obexelimab requires a partner or Zenas to build a commercial infrastructure if approved.
- Safety signals (hypersensitivity 16.5% vs 11.3%) may draw regulatory scrutiny despite overall favorable profile.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297346 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
Press Release
| $18.56 $18.38 | ▼ −0.97% | ▼ −1.29% | $17.61 (−5.12%) |
|
May 19, 2026
21d ago
|
Press Release
| $17.84 $18.53 | ▲ +3.84% | ▲ +1.59% | $17.61 (−1.29%) |
|
May 13, 2026
27d ago
|
Press Release
| $19.93 $17.84 | ▼ −10.49% | ▼ −9.33% | $17.61 (−11.64%) |
|
May 13, 2026
27d ago
|
8-K
| $19.93 $17.84 | ▼ −10.49% | ▼ −9.33% | $17.61 (−11.64%) |
|
May 13, 2026
27d ago
|
Press Release
| $19.93 $17.84 | ▼ −10.49% | ▼ −9.33% | $17.61 (−11.64%) |
|
Mar 31, 2026
10w ago
|
Insider Cluster
| $19.55 $20.86 | ▲ +6.70% | ▲ +2.76% | $17.61 (−9.92%) |
|
Mar 27, 2026
10w ago
|
Press Release
| $18.21 $22.26 | ▲ +22.24% | ▲ +18.38% | $17.61 (−3.29%) |
|
Mar 26, 2026
10w ago
|
424B5
| $18.21 $22.26 | ▲ +22.24% | ▲ +18.38% | $17.61 (−3.29%) |
|
Mar 26, 2026
10w ago
|
424B5
| $18.21 $22.26 | ▲ +22.24% | ▲ +18.38% | $17.61 (−3.29%) |
|
Mar 16, 2026
12w ago
|
DEFA14A
| $23.23 $20.63 | ▼ −11.19% | ▼ −9.15% | $17.61 (−24.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access